Tuesday, July 14, 2015
Investigational Aerosolized Ebola Vaccine Shows Promise in Nonhuman Primates
An experimental aerosolized (inhalable) vaccine fully protected four rhesus macaques exposed to Zaire Ebolavirus, according to new findings published in The Journal of Clinical Investigation. Investigators found the candidate vaccine—an aerosolized version of HPIV3/EboGP, which is based on the human parainfluenza virus type 3—also induced a robust immune response in the monkeys. Together, these findings provide the basis for advancing the experimental vaccine into clinical trials.